Shanghai Microport Endovascular Medtech (Group) Co., Ltd. reported a net profit of 429 million yuan for the first three quarters, marking a year-on-year decline of 22.46%.
The company specializes in endovascular medical devices and has faced market challenges impacting profitability. Investors are advised to carefully assess risks before making decisions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments